We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Deletions Affect Rapid Diagnostic Tests for Malaria

By LabMedica International staff writers
Posted on 25 Jul 2019
Prompt and accurate diagnosis of malaria is crucial for malaria case-management and control and elimination programmes. More...
While malaria diagnosis was historically based on symptoms alone, guidelines state that parasite-based diagnosis of malaria should be confirmed before treatment is given.

Malaria rapid diagnostic tests (mRDT) that target histidine-rich protein 2 (HRP2) are important tools for Plasmodium falciparum diagnosis. Parasites with pfhrp2/3 gene deletions threaten the use of these mRDTs, and have been reported in Africa, Asia, and South America. The absence of both HRP2 and HRP3 renders the parasites undetectable by HRP2-based mRDTs.

Scientists at the London School of Hygiene & Tropical Medicine (London, UK) and their colleagues analyzed P. falciparum parasites identified in human blood samples from three malaria studies in Ghana, Tanzania and Uganda. They analyzed 911 dried blood spots 165 from Ghana, 176 from Tanzania and 570 from Uganda (570). P. falciparum infection was confirmed by 18SrDNA polymerase-chain reaction (PCR), and pfhrp2/3 genes were genotyped.

True pfhrp2/3 gene deletions were confirmed if samples were (1) microscopy positive, (2) 18SrDNA polymerase chain (PCR) positive, (3) positive for merozoite surface protein genes by PCR, or positive by loop-mediated isothermal amplification (LAMP), and (4) quantitative PCR positive with > 5 parasites/µL. To confirm the deletion of pfhrp2 and pfhrp3 genes, PCR of two other single copy genes was performed.

The team reported that among the samples from Ghana, 107/165 (64.9%) were recorded as positive by mRDT and 82/165 (49.7%) by microscopy. In Tanzania, 72/171 (53.8%) samples were recorded as positive by mRDT, while 140/176 (79.6%) were positive by microscopy. Of the 570 Uganda samples, 258/570 (45.3%) were recorded as positive by mRDT, and 203 (35.6%) were positive by microscopy. No pfhrp2/3 deletions were detected in samples from Ghana, but deletions were identified in Tanzania (three pfhrp2; two pfhrp3) and Uganda (seven pfhrp2; two pfhrp3). Of the 10 samples with pfhrp2 deletions, nine tested negative by HRP2-based mRDT.

The authors concluded that the presence of pfhrp2/3 deletions in Tanzania and Uganda, along with reports of pfhrp2/3-deleted parasites in neighboring countries, reinforces the need for systematic surveillance to monitor the reliability of mRDTs in malaria-endemic countries. The study was published on June 28, 2019, in the Journal of Infectious Diseases.

Related Links:
London School of Hygiene & Tropical Medicine


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.